Companies / Japan
Novartis Launches Femara In Japan
May 2006 | Product LaunchSwiss drugmaker Novartis and co-marketing partner Chugai have launched the aromatase inhibitor Femara (letrozole), indicated for post menopausal breast cancers, on the Japanese market. The drug's market segment was valued at some US$180mn in 2005, according to analysts. Some 40,000 Japanese women are diagnosed with the disease each year. By 2013, Novartis expects to have sales of the drug worth some US$78mn, but the drug is likely to compete with AstraZeneca Arimidex and Pfizer Aromasin in
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
